Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.46 NOK | -2.50% | -6.83% | +12.35% |
Valuation
Fiscal Period: December | 2023 | 2024 | 2025 |
---|---|---|---|
Capitalization 1 | 218.8 | 218.8 | - |
Enterprise Value (EV) 1 | 194.7 | 157 | 218.8 |
P/E ratio | - | - | - |
Yield | - | - | - |
Capitalization / Revenue | 48.8 x | 34.7 x | 16.8 x |
EV / Revenue | 48.8 x | 24.9 x | 16.8 x |
EV / EBITDA | -2.01 x | -2.22 x | -4.77 x |
EV / FCF | - | - | - |
FCF Yield | - | - | - |
Price to Book | - | - | - |
Nbr of stocks (in thousands) | 40,068 | 40,068 | - |
Reference price 2 | 5.460 | 5.460 | 5.460 |
Announcement Date | 24-02-29 | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|
Net sales 1 | - | 3.991 | 6.3 | 13 |
EBITDA 1 | - | -96.72 | -70.7 | -45.9 |
EBIT 1 | - | -96.78 | -70.7 | -45.9 |
Operating Margin | - | -2,425.08% | -1,122.22% | -353.08% |
Earnings before Tax (EBT) | -56.01 | -87.94 | - | - |
Net income | -56.01 | -87.94 | - | - |
Net margin | - | -2,203.38% | - | - |
EPS | - | - | - | - |
Free Cash Flow | - | - | - | - |
FCF margin | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - |
Dividend per Share | - | - | - | - |
Announcement Date | 23-02-16 | 24-02-29 | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|
Net Debt 1 | - | - | - | - |
Net Cash position 1 | - | 49.6 | 61.8 | - |
Leverage (Debt/EBITDA) | - | - | - | - |
Free Cash Flow | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - |
Assets | - | - | - | - |
Book Value Per Share | - | - | - | - |
Cash Flow per Share | - | - | - | - |
Capex | - | - | - | - |
Capex / Sales | - | - | - | - |
Announcement Date | 23-02-16 | 24-02-29 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+12.35% | 20.11M | |
+23.37% | 47.02B | |
+48.83% | 41.86B | |
-0.94% | 41.76B | |
-5.86% | 28.8B | |
+11.29% | 26.05B | |
-20.92% | 19.15B | |
+3.20% | 12.55B | |
-2.67% | 11.82B | |
+30.23% | 12.34B |
- Stock Market
- Equities
- LYTIX Stock
- Financials Lytix Biopharma